StockData
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR) stock

AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$3.99+0.03 (+0.76%)

Close on Nov 18, 2026Market cap $320.02MP/E –Yield –

Atea Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Atea Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$183.61M. For fiscal 2025 it was -$180.89M. The highest annual figure on record is $138.38M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$180.89M–
FY2024Dec 31, 2024-$192.95M–
FY2023Dec 31, 2023-$164.16M–
FY2022Dec 31, 2022-$130.65M-194.4%
FY2021Dec 31, 2021$138.38M–
FY2020Dec 31, 2020-$11.03M–
FY2019Dec 31, 2019-$14.61M–
FY2018Dec 31, 2018-$9.48M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$35.10M–
Q1 FY2026Mar 31, 2026-$48.01M–
Q4 FY2025Dec 31, 2025-$54.93M–
Q3 FY2025Sep 30, 2025-$45.57M–
Q2 FY2025Jun 30, 2025-$41.35M–
Q1 FY2025Mar 31, 2025-$39.04M–
Q4 FY2024Dec 31, 2024-$39.03M–
Q3 FY2024Sep 30, 2024-$37.20M–
Q2 FY2024Jun 30, 2024-$46.92M–
Q1 FY2024Mar 31, 2024-$69.81M–
Q4 FY2023Dec 31, 2023-$46.57M–
Q3 FY2023Sep 30, 2023-$40.79M–
Q2 FY2023Jun 30, 2023-$35.24M–
Q1 FY2023Mar 31, 2023-$41.57M–
Q4 FY2022Dec 31, 2022-$39.90M-132.9%
Q3 FY2022Sep 30, 2022-$16.28M–
Q2 FY2022Jun 30, 2022-$32.30M-471.8%
Q1 FY2022Mar 31, 2022-$42.18M-237.6%
Q4 FY2021Dec 31, 2021$121.18M+486.9%
Q3 FY2021Sep 30, 2021-$22.15M–
Q2 FY2021Jun 30, 2021$8.69M–
Q1 FY2021Mar 31, 2021$30.66M–
Q4 FY2020Dec 31, 2020$20.65M–
Q3 FY2020Sep 30, 2020-$17.63M–
Q2 FY2020Jun 30, 2020-$10.00M–
Q1 FY2020Mar 31, 2020-$4.05M–
Q4 FY2019Dec 31, 2019-$4.75M–
Q3 FY2019Sep 30, 2019-$3.77M–

More Atea Pharmaceuticals figures

See a number that looks wrong?